Illumina is to make a 5,000-genome autism database available through BaseSpace. The deal will enable researchers to analyze the genomes of people with autism and their families using tools built into Illumina's cloud computing platform.
Welcome to Dx Digest, where FierceMedicalDevices highlights the highs and sometimes lows of the past week in the diagnostics industry. Invitae expanded its hereditary cancer and epilepsy test menu; sequencing giant Illumina announced that it would join forces with the Hartwell Foundation's Hartwell Autism Research and Technology Initiative to build the largest shared genomic database for autism; and Thermo Fisher Scientific gained more traction in the companion diagnostics realm.
In this week's Dx Digest, Illumina unveiled a $250 million share repurchase program, Quest Diagnostics inked a deal with lab data analytics firm Medivo to use its data sets to help match patients to new drug therapies, and Foundation Medicine reported a beat on revenues for the third quarter, even though it missed the Street's expectations on earnings.
Illumina issued a profit warning due to poor sales of its NextSeq Series Desktop Sequencer as well as weakness in Europe and Japan, sending its stock tumbling 10% for the day. The company expects earnings per share to fall below consensus expectations, consistent with a 3% revenue shortfall.
Illumina has detailed how it intends to start generating income from its cloud app platform BaseSpace. The plan includes the creation of two paid-for packages that bundle together assorted features, some of which are targeted specifically at larger organizations.
Illumina is joining forces with China's Amoy Diagnostics to create next-generation sequencing cancer tests for the Chinese clinical market, expanding its footprint in the country while strengthening its commitment to developing innovative technology for the disease.
Ilumina kicked off commercialization of its next-generation solid tumor sequencing panel to help researchers identify 15 commonly mutated genes in samples.
As diagnostics companies zero in on a fast-growing liquid biopsy field, Illumina is teaming up with Memorial Sloan Kettering Cancer Center to study circulating tumor DNA for cancer treatment.
Memorial Sloan Kettering and Illumina have partnered to do research to better understand the biology of circulating tumor DNA. The NYC-based cancer center and the genomics giant expect to develop new cancer diagnostic and monitoring strategies based upon that work.
HudsonAlpha has rejigged its operation to cope with the torrent of genomes it unleashed when it installed an Illumina HiSeq X Ten. The new model is underpinned by Dragen, the processor Edico Genome has designed specifically to deal with the demands of sequencing data analysis.